Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). MRT-6160 (DDY391) Phase 2 study initiated in participants with Sjögren’s disease.
Monte Rosa Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- MRT-6160 (DDY391) Phase 2 study initiated in participants with Sjögren’s disease
- Novartis conducting the study under its collaboration with Monte Rosa
- Milestone supports clinical advancement of Monte Rosa’s VAV1-directed molecular glue degrader
- Press release furnished as Exhibit 99.1 for milestone details
Item 8.01 · Other Events
- Phase 2 initiation for MRT-6160 triggered a $50 million milestone payment from Novartis
- Novartis holds exclusive worldwide development, manufacturing, and commercialization rights
- Monte Rosa eligible for up to $2.1 billion in development, regulatory, and sales milestones
- Milestone opportunity begins with Phase 2 initiation, increasing non-dilutive funding potential
- Future payments and MRT-6160 outcomes remain dependent on clinical, regulatory, and commercial execution
Item EX-99.1 · Exhibit EX-99.1
- Novartis initiated Phase 2a/b Sjögren’s study for MRT-6160, advancing the partnered program toward dose selection for Phase 3
- Monte Rosa to receive $50 million milestone tied to the study’s first patient visit
- Novartis funds Phase 2 development, reducing Monte Rosa’s near-term clinical cash burden
- Monte Rosa eligible for up to $2.1 billion in development, regulatory, and sales milestones
- U.S. economics include 30% profit-and-loss sharing, plus tiered ex-U.S. royalties
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monte Rosa Therapeutics, Inc. 8-K filings
Get the next GLUE 8-K as it lands
Follow GLUE for push alerts, or ask the research agent what this filing means.